| Zacks Company Profile for Ironwood Pharmaceuticals, Inc. (IRWD : NSDQ) |
|
|
| |
| • Company Description |
| Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Number of Employees: 253 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.78 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,675,208 shares |
| Shares Outstanding: 161.82 (millions) |
| Market Capitalization: $125.56 (millions) |
| Beta: 0.30 |
| 52 Week High: $7.11 |
| 52 Week Low: $0.53 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
16.08% |
11.74% |
| 12 Week |
6.77% |
-10.19% |
| Year To Date |
-82.49% |
-83.60% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Thomas McCourt - Chief Executive Officer and Director
Julie H. McHugh - Chairman
Gregory Martini - Senior Vice President; Chief Financial Officer
Ronald Silver - Senior Vice President; Corporate Controller
Mark Currie - Director
|
|
Peer Information
Ironwood Pharmaceuticals, Inc. (GSAC)
Ironwood Pharmaceuticals, Inc. (CASI)
Ironwood Pharmaceuticals, Inc. (ALCD.)
Ironwood Pharmaceuticals, Inc. (OMNN)
Ironwood Pharmaceuticals, Inc. (CGPI.)
Ironwood Pharmaceuticals, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 46333X108
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 161.82
Most Recent Split Date: (:1)
Beta: 0.30
Market Capitalization: $125.56 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.09 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $0.14 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
